Alzheimer’s disease is classified as a neurological disorder, specifically a neurodegenerative disease, not a mental illness. It is caused by measurable physical changes in the brain, including the buildup of abnormal proteins and progressive loss of brain tissue. But this clean label obscures a messier reality: Alzheimer’s routinely produces psychiatric symptoms like depression, anxiety, and psychosis, and for decades it has lived in the gray zone between neurology and psychiatry in ways that affect how patients are diagnosed, treated, and perceived.
Why the Question Comes Up
The confusion is understandable, because the dividing line between “neurological” and “psychiatric” has always been somewhat artificial. The traditional distinction goes like this: neurology deals with diseases of the nervous system that have a demonstrable physical basis in brain tissue, while psychiatry handles behavioral disturbances that lack a known structural cause.1PubMed Central. The wall between neurology and psychiatry By that definition, Alzheimer’s falls squarely on the neurological side. You can see the damage on brain scans, find the abnormal proteins in spinal fluid, and watch the tissue shrink over time.
But people with Alzheimer’s don’t typically show up at the doctor saying “I think my hippocampus is shrinking.” They show up because they’re forgetting things, feeling confused, getting anxious, or behaving in ways their families find alarming. Those symptoms look a lot like what psychiatry deals with, and in the early stages of the disease, before the cognitive decline becomes obvious, Alzheimer’s can be mistaken for depression or other psychiatric conditions.2PubMed Central. Early-onset Alzheimer’s disease with depression as the first symptom: a case report with literature review This overlap is part of why people wonder whether Alzheimer’s “really” belongs in the mental illness category.
What Makes Alzheimer’s a Neurological Disease
Alzheimer’s has a clearly identifiable biological signature in the brain, which is the core reason it is classified as neurological rather than psychiatric. Research frameworks now define the disease not by its symptoms but by three categories of biological markers: amyloid-beta plaques, pathological tau tangles, and neurodegeneration (the loss of neurons and brain volume). This is known as the A/T/N framework, and it allows researchers to identify Alzheimer’s even in people who haven’t developed noticeable symptoms yet.3PubMed Central. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
The National Institute on Aging and the Alzheimer’s Association have formalized this biological approach. Under their research framework, Alzheimer’s is defined by its underlying pathologic processes, which can be documented by postmortem examination or during life by biomarkers. The diagnosis is no longer based on clinical symptoms alone; it has shifted from a syndromal definition to a biological one.4PubMed Central. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease Under this framework, a person with the characteristic brain protein abnormalities can be considered to have Alzheimer’s disease even before symptoms appear.5PubMed Central. Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?
The physical destruction is extensive. Brain imaging studies show that atrophy in Alzheimer’s progresses across dozens of brain regions spanning the occipital, frontal, temporal, parietal, and cingulate cortices, well beyond what normal aging would produce.6Brain Communications. Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer’s disease Blood-based biomarkers can now track this process: people with both amyloid abnormalities and neurodegeneration markers in their blood show the fastest rates of cognitive decline and brain shrinkage.7PubMed Central. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease None of this is speculative. It is measurable, progressive tissue destruction, which is exactly what places Alzheimer’s in the neurological category.
How Diagnostic Manuals Handle It
If you’ve ever seen Alzheimer’s listed alongside psychiatric conditions, that probably happened because of where it sits in the DSM-5-TR, the manual used by psychiatrists and psychologists. The DSM-5-TR classifies Alzheimer’s under “neurocognitive disorders,” requiring a decline in memory and learning plus at least one other cognitive domain, along with interference in daily functioning.8PubMed Central. Alzheimer’s Disease is a Disorder of Consciousness The DSM is primarily a psychiatric reference manual, so the fact that Alzheimer’s appears in it can give the impression that it’s a psychiatric condition. But “neurocognitive disorder” is the DSM’s way of acknowledging that these conditions have a known biological basis. The DSM includes them because clinicians in mental health settings encounter and diagnose them, not because the field considers them psychiatric in origin.
The International Classification of Diseases (ICD-11) takes a similar approach. The chapter on “neurocognitive disorders” retains the syndromic classification from ICD-10 but adds severity levels and gives greater weight to the behavioral and psychological symptoms that accompany dementia. This allows for more precise coding of the full clinical picture, recognizing that both the cognitive and psychiatric features matter for treatment and care planning.
So both major diagnostic systems place Alzheimer’s in a category that explicitly signals its neurological roots while acknowledging the psychiatric symptoms it produces. It’s a neurological disease that shows up in psychiatric manuals because it affects the mind so profoundly.
The Psychiatric Side of Alzheimer’s
Here is where the tidy “neurological, not mental illness” answer starts to feel incomplete. Alzheimer’s produces psychiatric symptoms in the vast majority of people who have it, and these symptoms are not minor side effects. They include depression, anxiety, apathy, agitation, psychosis (hallucinations and delusions), and severe sleep disturbances.9PubMed Central. Behavioral or neuropsychiatric symptoms of Alzheimer’s disease: from psychopathology to pharmacological management These neuropsychiatric symptoms are present across all stages of the disease and are among the most distressing features for both the person with Alzheimer’s and their caregivers.10PubMed Central. Neuropsychiatric symptoms in Alzheimer’s disease: Bridging mechanisms, management, and emerging innovations
These are not just unpleasant add-ons. They predict faster cognitive decline, earlier placement in institutional care, and worse outcomes overall. They are among the earliest signs of the disease, appearing even before the memory loss becomes clinically obvious, and they are often underrecognized and difficult to treat.11PubMed Central. Neuropsychiatric signs and symptoms of Alzheimer’s disease: New treatment paradigms Researchers have increasingly framed these psychiatric symptoms not just as consequences of brain damage but as clinical markers of progression along the Alzheimer’s spectrum.9PubMed Central. Behavioral or neuropsychiatric symptoms of Alzheimer’s disease: from psychopathology to pharmacological management
This creates practical problems. When a 58-year-old develops depression and subtle personality changes, a clinician might reasonably diagnose a mood disorder and prescribe antidepressants. It can take months or years before the underlying neurodegenerative process becomes apparent. Early-onset Alzheimer’s, which strikes before age 65, is especially prone to this kind of misdiagnosis because its initial presentation frequently mimics psychiatric illness.2PubMed Central. Early-onset Alzheimer’s disease with depression as the first symptom: a case report with literature review
Shared Biology Between Alzheimer’s and Psychiatric Disorders
The boundary between Alzheimer’s and psychiatric illness gets blurrier at the genetic and molecular level. Studies mapping the genetic architecture of Alzheimer’s alongside major depression have found that roughly 38% of Alzheimer’s causal genetic variants overlap with those linked to depression. That’s a strikingly large overlap given that, by chance alone, only about four variants would be expected to be shared. The directions of effect are mixed, though, meaning some of those shared variants increase the risk of both conditions while others push in opposite directions.12PubMed Central. Genetic Overlap Between Alzheimer’s Disease and Depression Mapped Onto the Brain
The genetic connections extend beyond depression. Research has identified positive genetic correlations between Alzheimer’s and several psychiatric conditions, including neuroticism, major depression, bipolar disorder, PTSD, alcoholism, and insomnia.13Nature Communications. Shared mechanisms across the major psychiatric and neurodegenerative diseases There is also a weak but positive genetic correlation between schizophrenia and Alzheimer’s, and schizophrenia-related genetic risk scores have been linked to the development of psychosis in people who already have Alzheimer’s.14PubMed. Genetic overlap between schizophrenia spectrum disorders and Alzheimer’s disease: Current evidence and future directions – An integrative review
At the cellular level, inflammation appears to be a shared mechanism driving both neurodegenerative and psychiatric diseases. Brain inflammatory responses contribute to oxidative stress, neurotransmitter imbalances, and problems with the connections between neurons in both types of conditions. Neurodegenerative and psychiatric diseases, it turns out, share a surprisingly large number of disease mechanisms.15Frontiers in Cellular Neuroscience. Editorial: The role of inflammation in neurodegenerative and psychiatric disorders This doesn’t make Alzheimer’s a psychiatric condition, but it does mean the wall between “brain diseases” and “mind diseases” is thinner than the categorical labels suggest.
Brain Network Disruptions That Bridge Both Worlds
One of the more revealing findings in modern neuroimaging is that Alzheimer’s disrupts the same brain network that is altered in several psychiatric conditions. The default mode network is a set of brain regions that are active when you’re daydreaming, recalling memories, or thinking about yourself and others. It becomes less synchronized and less active at rest in people with Alzheimer’s and even in people at genetic risk for the disease.16PubMed Central. The default mode network in healthy aging and Alzheimer’s disease
Meta-analyses of brain imaging studies have mapped out exactly where the default mode network breaks down in Alzheimer’s and in the earlier stage of mild cognitive impairment. Both conditions show decreased connectivity in key hubs of this network, including the medial prefrontal cortex and the precuneus. These are regions involved in self-awareness, memory retrieval, and social cognition. The shared disruption in these areas likely underpins not only the memory deficits but also the neuropsychiatric symptoms like apathy and social withdrawal that characterize Alzheimer’s.17PubMed. Shared and differing functional connectivity abnormalities of the default mode network in mild cognitive impairment and Alzheimer’s disease Disruptions in this same network have been observed in depression, schizophrenia, and other psychiatric conditions, which is part of why Alzheimer’s symptoms can mimic psychiatric illness on the surface.
Stigma and the Weight of Labels
Whether Alzheimer’s is called a neurological disorder or a mental illness isn’t just an academic distinction. It shapes how patients and their families are treated by society. Research on dementia stigma in the United States has shown that public attitudes toward people with dementia are influenced by how impaired they appear and by the respondent’s own characteristics, with stigmatizing views remaining common even in nationally representative samples.18Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Dementia stigma in the United States: variation by target gender, degree of impairment, and respondent characteristics
The stigma surrounding mental illness is well documented, and when Alzheimer’s is perceived as a mental health condition, that stigma can transfer. People with cognitive decline may face social isolation, reluctance from others to engage with them, and reduced access to rehabilitation and support resources. Even people with mild cognitive impairment can experience internal stress and withdrawal because of the social meaning attached to the label. Some researchers have argued that changing the terminology around cognitive disorders could reduce the negative psychological impact on patients and families.
Cultural context matters too. Studies of dementia awareness across different communities have found that lower levels of accurate knowledge about dementia and stronger culturally associated beliefs, such as the idea that memory loss is simply a normal part of aging, create barriers to diagnosis and care. Stigma associated with dementia is a significant barrier in many cultural contexts, further complicating how people understand and respond to the disease.19PubMed. Cross-cultural differences in dementia: the Sociocultural Health Belief Model
Who Treats Alzheimer’s and Why It Matters
The neurological-versus-psychiatric framing has real consequences for clinical care. In most health systems, neurologists manage the cognitive decline and prescribe the disease-modifying therapies (like the newer anti-amyloid antibodies), while psychiatrists or geriatric psychiatrists handle the behavioral symptoms like agitation, psychosis, and depression. This split means that a person with Alzheimer’s often needs care from both sides of the traditional divide, and coordination between the two can be patchy.
The treatment of psychiatric symptoms in Alzheimer’s illustrates the tension. Antipsychotic medications have been widely used to manage agitation and psychosis in dementia, but a boxed warning from the FDA flagged increased mortality risk in elderly dementia patients taking these drugs. Research on the impact of that warning found that mortality risk in this population fluctuated and actually trended upward after the warning was introduced, reflecting the complex tradeoffs clinicians face when managing severe behavioral symptoms with limited pharmacological options.20JAMA Network Open. Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia This challenge lives at the intersection of neurology and psychiatry: the symptoms are psychiatric, the underlying cause is neurological, and the treatments carry risks that neither specialty can fully manage alone.
Growing recognition of this overlap has fueled calls to bridge the gap between the two fields. The concept of “neuropsychiatric disorders,” conditions that straddle both disciplines, has been gaining traction. Researchers have emphasized the need to move beyond traditional disciplinary boundaries and explore common neurobiological pathways, arguing that collaboration between neurology and psychiatry will ultimately improve how these diseases are understood and treated.21PubMed Central. Neuropsychiatric Disorders: Bridging the Gap Between Neurology and Psychiatry
Decision-Making Capacity and Legal Implications
One area where the neurological-versus-psychiatric classification has immediate practical consequences is in assessing whether a person with Alzheimer’s can still make their own decisions. Capacity is a clinical judgment made by a doctor about whether a patient can understand and make a specific decision, while competency is a broader legal determination made by a judge.22PubMed Central. Capacity issues and decision-making in dementia Both medical and legal professionals face the challenge of assessing these abilities in people with dementia, where decision-making can be impaired in unpredictable and fluctuating ways.23PubMed Central. Dementia, Decision Making, and Capacity
Both neurologists and psychiatrists may be called upon to evaluate capacity, and which specialist gets consulted can depend on how the disease is classified in a given health system and on local legal conventions.24PubMed. Assessment of Medical Decision-making Capacity in Patients With Dementia In jurisdictions that frame Alzheimer’s primarily as a neurological condition, the assessment may fall to a neurologist who focuses on cognitive test scores. Where psychiatric involvement is standard, the evaluation may also weigh emotional and behavioral factors. Neither approach is inherently better, but the framing influences who does the assessment and how it’s conducted. For families navigating questions about financial management, living arrangements, or medical consent, the practical answer to “Is this a neurological or psychiatric condition?” can determine which professionals they’re referred to and what kind of evaluation their loved one receives.
When Depression and Cognitive Complaints Overlap
A particularly tricky clinical scenario involves older adults who report that their memory and thinking are getting worse. Subjective cognitive decline, the feeling that your mind isn’t as sharp as it used to be, is often flagged as a potential early warning sign of Alzheimer’s. But research in clinic-based populations has found that these subjective complaints correlate more strongly with depression symptoms than with actual cognitive performance on objective tests.25The Journals of Gerontology: Series B. Subjective Cognitive Decline Correlates With Depression Symptoms and Not With Concurrent Objective Cognition in a Clinic-Based Sample of Older Adults In other words, when an older person says “my memory is failing,” depression may be driving that perception more than actual brain decline.
This finding cuts both ways. It means that some people who worry they’re developing Alzheimer’s are actually experiencing depression, a treatable condition. But it also means that depression can mask early cognitive changes by making it hard to tell whether complaints reflect a mood disorder, genuine neurodegeneration, or both. Clinicians evaluating cognitive complaints in older adults need to screen carefully for depression and not assume that every memory complaint signals the beginning of Alzheimer’s. Conversely, dismissing all cognitive complaints as “just depression” can delay recognition of real neurodegenerative disease. The two conditions feed into each other in ways that make clean separation difficult, reinforcing the reality that Alzheimer’s sits at the intersection of neurology and psychiatry even when the formal classification places it on one side.